To evaluate the efficacy and dosing considerations of low-dose atropine in managing childhood myopia.
Approach:
Regulatory Context: Low-dose atropine has gained attention with the European approval of Ryjunea® and is supported by randomized clinical trials.
Dose Variability: The term 'low-dose atropine' encompasses various concentrations, which may have different clinical effects.
Trial Analysis: Existing studies vary in design, making direct comparisons difficult and complicating treatment recommendations.
Endpoints for Success: Current trial endpoints may need to be supplemented with trajectory-based measures for better clinical interpretation.
Key Findings:
Low-dose atropine can reduce myopia progression, but the effect varies by concentration.
0.05% atropine generally shows the strongest efficacy among lower doses.
0.01% atropine has a modest effect on axial elongation, which may not be sufficient for all patients.
The evidence base for 0.01% atropine is substantial but should be interpreted cautiously.
Interpretation:
While low-dose atropine is effective in reducing myopia progression, the adequacy of treatment depends on individual patient factors and specific growth targets.
Limitations:
Most existing studies were not designed to test against age-matched physiological growth targets.
Variability in trial designs complicates the establishment of universal treatment recommendations.
Conclusion:
Further research is needed to validate trajectory-based endpoints and to determine the optimal dosing strategy for low-dose atropine in childhood myopia management.
